Day One Biopharmaceuticals, Inc. 8-K/A

What Happened

• On March 9, 2026, Day One Biopharmaceuticals, Inc. filed an amendment to its prior Form 8-K to amend Item 9.01 of the Original Report. The amendment adds the audited consolidated financial statements of the Target (as defined in the Original Report) for the years ended December 31, 2024 and December 31, 2023, and the unaudited interim condensed consolidated financial statements of the Target for the three- and nine-month periods ended September 30, 2025. The filing also updates related information in the Original Report.

Key Details

• Amended Item 9.01 to include audited consolidated financial statements of the Target for the years ended Dec 31, 2024 and Dec 31, 2023.
• Included unaudited interim condensed consolidated financial statements for the Target for the three and nine months ended Sep 30, 2025.
• Filing date: March 9, 2026; this supplements the company’s previously filed Original Report (Target defined therein).

Why It Matters

• Investors now have the Target’s audited historical annual financials and recent interim results included in Day One’s filings, which are important for evaluating the financial condition and results of operations of the Target as disclosed in connection with the Original Report.
• Inclusion of these financial statements is a routine but material disclosure step in transactions and regulatory reporting; it improves transparency about the Target’s historical performance and supports subsequent shareholder, regulatory or integration processes tied to the previously disclosed transaction.